Medexus appoints new CFO

0

TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) – Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the appointment of Marcel Konrad to the position of Chief Financial Officer Officer of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is stepping down after nearly a decade in this post. Mr. Boivin has agreed to remain in an advisory capacity to help ensure an orderly transition of responsibilities to Mr. Konrad over the next three months or so.

“I want to take this opportunity on behalf of all of us at Medexus to thank Roland for all of his efforts and dedicated service and wish him the best in his future endeavors,” said Ken d’Entremont, CEO of the company. . .

“I am grateful to have had the opportunity to work with the entire Medexus team and to have played a key role in the company’s transition from a small, uniquely Canadian player to a North American business leader. in innovative orphan drugs and products for rare diseases ”says Roland Boivin. “I am confident that Medexus is well positioned to continue to prosper and look forward to working with Mr. Konrad, Ken and the management team to ensure a smooth transition.

Looking ahead, Mr. Konrad brings over 20 years of accounting, finance and business experience in various global markets, including the United States. Mr. Konrad joins the company from CareDx, Inc. (Nasdaq: CDNA), a precision medicine solutions company, where he was Senior Vice President of Finance and Accounting and Vice President, Controller of company since 2018, including a stint as interim CFO. Agent in early 2021. While working at CareDx, Inc., Mr. Konrad was tasked with evolving multinational accounting, financial and business operations, including streamlining processes and systems while navigating the world. integration of various cross-border financing and acquisitions.

Prior to joining CareDx, Inc., Mr. Konrad held similar positions at Santen Inc., a U.S. subsidiary of a publicly traded Japanese pharmaceutical company with global operations, and held various positions at Novartis Pharmaceuticals, USA. United and Switzerland. Mr. Konrad holds an International MBA from the University of San Diego and graduated in Business Administration from HEC Lausanne, University of Lausanne, Switzerland. Mr. Konrad is an active public accountant in the United States and during his tenure at Novartis completed the Financial Leadership Program at Harvard Business School.

“Marcel brings to Medexus a combination of financial acumen, strategic and industry expertise and experience in global operational leadership that will be invaluable to the Company. We look forward to Marcel starting his Medexus journey, ”said Mr. d’Entremont.

About Medexus Pharmaceuticals Inc.

Medexus is a leader in innovative rare disease treatment solutions with a strong North American business platform. From a proven, best-in-class product base, we are building a highly differentiated business with a portfolio of innovative and high-value products for orphans and rare diseases that will support our growth over the next decade. The company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values ​​of quality, innovation, customer service and teamwork. Medexus Pharmaceuticals focuses on the therapeutic areas of autoimmune diseases, hematology and allergies. The Company’s main products are: Rasuvo ™ and Metoject®, a unique formulation of methotrexate (automatic pen and pre-filled syringe) designed to treat rheumatoid arthritis and other autoimmune diseases; IXINITY®, a recombinant factor IX intravenous therapeutic agent for use in patients 12 years of age or older with hemophilia B – an inherited bleeding disorder characterized by a deficiency of coagulation factor IX in the blood, which is required to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.

For more information please contact:

Ken d’Entremont, Chief Executive Officer
Médexus Pharma inc.
Phone. : 905-676-0003
Email: ken.dentremont@medexus.com

Investor Relations (United States):
Crescendo Communications, LLC
Phone. : + 1-212-671-1020
Email: mdp@crescendo-ir.com

Investor Relations (Canada):
Tina Byers
Capital of Adelaide
Phone. : 905-330-3275
Email: tina@adcap.ca


Source link

Share.

Leave A Reply